Raisio plc: Financial Statements Bulletin 2018 Raisio

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
44
Raisio plc: Financial Statements Bulletin 2018

Raisio plc, Financial Statements Bulletin 12 February 2019 at 8.30 Finnish time

RAISIO IS NOW AN INTERNATIONAL BRAND HOUSE FOCUSING ON HEALTHY FOOD

January-December 2018, continuing operations

  • The Group’s net sales totalled EUR 228.2 (234.6) million. Comparable EBIT was EUR 25.6 (35.9) million, accounting for 11.2 (15.3) % of net sales. EBIT was EUR 16.6 (54.1) million, accounting for 7.3 (23.0) % of net sales. EBIT for the comparison year includes sales profits of EUR 28.0 million for the Southall factory property.
  • The Healthy Food Division’s net sales totalled EUR 201.1 (201.4) million. Comparable EBIT was EUR 29.8 (39.3) million, accounting for 14.8 (19.5) % of net sales. EBIT was EUR 30.8 (38.4) million, accounting for 15.3 (19.0) % of net sales.
  • The Raisioaqua Division’s net sales totalled EUR 25.9 (31.8) million. EBIT totalled EUR -0.8 (2.4) million.
  • The Board of Directors’ dividend proposal to the Annual General Meeting is EUR 0.16 per share, of which EUR 0.04 as an extra dividend.

October-December 2018, continuing operations

  • The Group’s net sales totalled EUR 55.6 (53.7) million. Comparable EBIT was EUR 5.0 (6.7) million, accounting for 9.0 (12.5) % of net sales. EBIT totalled EUR -2.1 (-2.4) million.
  • The Healthy Food Division’s net sales totalled EUR 53.3 (50.6) million. Comparable EBIT was EUR 7.4 (9.5) million, accounting for 13.8 (18.7) % of net sales. EBIT was EUR 8.5 (8.5) million, accounting for 16.0 (16.9) % of net sales.
  • The Raisioaqua Division’s net sales totalled EUR 2.0 (2.7) million. EBIT totalled EUR -1.1 (-0.7) million.

CEO’S REVIEW

“The year 2018 was a period of strong renewal and construction of the new for Raisio. The company now has a clear focus: healthy food. Our goal is to be an innovative and increasingly international brand house.

We have now built a solid foundation for our next steps. Our purpose and values defined together with the staff create the basis for all our work and guide the decision-making. In line with its strategy, Raisio will focus on securing the growth and profitability of its core operations in 2019.

In 2018, several separate events affected Raisio’s sales and profitability. The most significant impacts on EBIT were the EBIT decrease of EUR 2.5 million on the comparison year due to the Russian fish feed import ban, planned growth of marketing costs and challenges faced in the Russian and Polish consumer product markets. EBIT for Russia and Poland declined by EUR 2 million on the comparison year. Raisio has identified the problem areas in these markets, carried out corrective measures and managed to turn the direction of the businesses. Furthermore, exceptionally poor harvest in Finland together with a grain price increase of up to 60 per cent decreased profitability. Raisio promptly reacted to the situation with price changes.

For Raisioaqua, the second half of 2018 was exceptional as the Russian authorities closed the border in August. After the border was reopened in December, Raisioaqua continued to finalise the 2019 fish feed contracts with its Russian customers, whose confidence in Raisioaqua remains very high.   Raisio’s most significant novelty was launched in the autumn: Elovena Muru Oat Mince, a plant-based protein product for versatile cooking. Elovena Muru has been very well received by consumers. The product has shown its ability to grow the whole category and to compete for the market leadership.

Our Benecol product range expanded into new categories. We increased our marketing investment to boost the sales of novelties and to gain new Benecol consumers. In our key Benecol product markets, we have started long-term work to increase healthcare professionals’ knowledge on cholesterol and on safe and effective Benecol products proven to lower cholesterol.

Raisio’s balance sheet has further strengthened, which enables the company to implement its long-term growth strategy.”

OUTLOOK 2019

In 2019, Raisio expects its net sales for continuing operations to grow (2018: EUR 228.2 million) and comparable EBIT to be over 10 per cent of net sales.

Raisio will continue its investments in the brands, R&D and the company’s own production in its most important product categories.

In Raisio, 12 February 2019

Raisio plc’s Board of Directors

Further information: Pekka Kuusniemi, President and CEO, tel. +358 50 537 3883 Toni Rannikko, CFO, tel. +358 40 078 8812 Heidi Hirvonen, Communications and IR Manager, tel. +358 50 567 3060

CEO’s video in English will be available on Raisio’s web site at www.raisio.com.

Raisio’s financial releases in 2019: - Report of the Board of Directors and Financial Statements for 2018 published 26 February 2019 - Annual Report for 2018 published in week 10 on the company’s website at www.raisio.com - Interim Report for January-March published 8 May 2019, - Half-Year Financial Report for January-June published 7 August 2019 - Interim Report for January-September published 6 November 2019

The interim report has not been audited.

Raisio plc

Raisio is an international company specialised in healthy, responsibly produced food. Our well-known brands include, for example, Benecol, Elovena, Nalle and Sunnuntai. In Raisio’s products, the focus is on well-being, health, good taste and sustainable development. Profitable growth is ensured through our strong expertise and passion for creating new. Raisio’s shares are listed on Nasdaq Helsinki Ltd. In 2017, the Group’s net sales for continuing operations totalled EUR 235 million and comparable EBIT was EUR 36 million. Our food is good for Health, Heart and Earth. For more information on Raisio go to www.raisio.com .

Distribution Nasdaq Key media www.raisio.com

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 1

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 1

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 4

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 8

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 9

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading

Top 5 Most Recently Viewed Articles

Combining Forces: Waters Corporation and BD to Lead Diagnostics

Updated Category News Views 331

Exciting Merger in the Life Sciences Sector In a significant move for the life sciences industry, Waters Corporation (NYSE: WAT) has officially announced its plans to merge with BD (Becton, Dickinson and Company) (NYSE: BDX). This merger aims to create a leading entity in the fields of regulated and high-volume testing. The combination is expected to harness the strengths...

Continue Reading
Citius Oncology Strengthens LYMPHIR Launch with New Partnership

Updated Category News Views 109

Citius Oncology Reinforces Distribution for LYMPHIR Citius Oncology, Inc. (Nasdaq: CTOR), a leading company in oncology therapeutics, has taken a significant step by partnering with Cencora, a global provider of pharmaceutical solutions. The newly signed distribution services agreement is aimed at enhancing commercial infrastructure and ensuring the successful launch of...

Continue Reading
Exploring Growth in Low-Code Development Platforms

Updated Category News Views 242

Surging Growth in Low-Code Development Platforms The demand for low-code development platforms is on the rise, with projected growth from USD 26.30 billion in 2025 up to USD 67.12 billion by 2030, at an impressive CAGR of 20.61%. This surge is primarily fueled by organizations adopting hybrid and multi-cloud strategies, making low-code tools essential for modernizing...

Continue Reading
Foresee Pharmaceuticals Unveils Promising Results for Linvemastat

Updated Category News Views 58

Foresee Pharmaceuticals Announces Groundbreaking Phase 1 Results Foresee Pharmaceuticals (TPEx: 6576) is excited to share notable updates regarding its Phase 1 clinical trial of linvemastat (FP-020), a distinctive and selective oral MMP-12 inhibitor. The trial, focused on assessing safety, tolerability, and pharmacokinetics, has been successfully completed and has...

Continue Reading
Unlocking Spring’s Real Estate Potential with Mistoria Group

Updated Category News Views 302

Why May is the Optimal Time for Real Estate Transactions As the weather warms and spring settles in, the real estate market bursts with activity. Leading property experts suggest that May is the prime month to either buy or sell a home. Mish Liyanage, the CEO of Mistoria Group, emphasizes that emerging market trends provide compelling reasons for homeowners and potential...

Continue Reading